非处方使用加巴喷丁类

David S. Baldwin, Vasilios Masdrakis
{"title":"非处方使用加巴喷丁类","authors":"David S. Baldwin,&nbsp;Vasilios Masdrakis","doi":"10.1016/j.intcar.2023.100164","DOIUrl":null,"url":null,"abstract":"<div><p>The gabapentinoid<span> drugs<span><span><span> gabapentin and </span>pregabalin are medications used clinically across a range of neurological and </span>psychiatric conditions<span>. They have analgesic<span><span><span>, anticonvulsant<span> and anxiolytic effects. Their specific licensed indications differ, and vary across countries, but include certain neurological problems such as focal seizures, peripheral </span></span>neuropathic pain<span><span>, spasticity in multiple sclerosis, and muscular symptoms in </span>motor neurone disease, and the psychological condition of </span></span>generalized anxiety disorder. However, in many countries, gabapentin and pregabalin are frequently prescribed outside the terms of their market authorisations, and non-prescribed use has become widespread and troublesome in many populations. Increasing concerns regarding non-prescribed use have led some regulatory authorities to designate gabapentin and pregabalin as controlled substances, with accompanying regulations regarding prescriptions. This review describes the pharmacological properties of gabapentin and pregabalin, highlights evidence regarding efficacy and tolerability, summarises the findings of investigations of potential hazards with these drugs, and concludes with guidance on the clinical management of non-prescribed use.</span></span></span></span></p></div>","PeriodicalId":100283,"journal":{"name":"Clinics in Integrated Care","volume":"21 ","pages":"Article 100164"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Non-prescribed use of gabapentinoids\",\"authors\":\"David S. Baldwin,&nbsp;Vasilios Masdrakis\",\"doi\":\"10.1016/j.intcar.2023.100164\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The gabapentinoid<span> drugs<span><span><span> gabapentin and </span>pregabalin are medications used clinically across a range of neurological and </span>psychiatric conditions<span>. They have analgesic<span><span><span>, anticonvulsant<span> and anxiolytic effects. Their specific licensed indications differ, and vary across countries, but include certain neurological problems such as focal seizures, peripheral </span></span>neuropathic pain<span><span>, spasticity in multiple sclerosis, and muscular symptoms in </span>motor neurone disease, and the psychological condition of </span></span>generalized anxiety disorder. However, in many countries, gabapentin and pregabalin are frequently prescribed outside the terms of their market authorisations, and non-prescribed use has become widespread and troublesome in many populations. Increasing concerns regarding non-prescribed use have led some regulatory authorities to designate gabapentin and pregabalin as controlled substances, with accompanying regulations regarding prescriptions. This review describes the pharmacological properties of gabapentin and pregabalin, highlights evidence regarding efficacy and tolerability, summarises the findings of investigations of potential hazards with these drugs, and concludes with guidance on the clinical management of non-prescribed use.</span></span></span></span></p></div>\",\"PeriodicalId\":100283,\"journal\":{\"name\":\"Clinics in Integrated Care\",\"volume\":\"21 \",\"pages\":\"Article 100164\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinics in Integrated Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666869623000271\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics in Integrated Care","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666869623000271","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

加巴喷丁类药物加巴喷汀和普瑞巴林是临床上用于一系列神经和精神疾病的药物。它们具有镇痛、抗惊厥和抗焦虑的作用。它们的具体许可适应症各不相同,各国也有所不同,但包括某些神经系统问题,如局灶性癫痫发作、周围神经性疼痛、多发性硬化症的痉挛、运动神经元疾病的肌肉症状以及广泛性焦虑症的心理状况。然而,在许多国家,加巴喷丁和普瑞巴林经常在其市场授权条款之外使用,非处方使用在许多人群中变得普遍和麻烦。对非处方使用的日益担忧导致一些监管机构将加巴喷丁和普瑞巴林指定为受控物质,并制定了相关处方规定。这篇综述描述了加巴喷丁和普瑞巴林的药理学特性,强调了有关疗效和耐受性的证据,总结了这些药物潜在危害的调查结果,并总结了非处方用药的临床管理指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Non-prescribed use of gabapentinoids

The gabapentinoid drugs gabapentin and pregabalin are medications used clinically across a range of neurological and psychiatric conditions. They have analgesic, anticonvulsant and anxiolytic effects. Their specific licensed indications differ, and vary across countries, but include certain neurological problems such as focal seizures, peripheral neuropathic pain, spasticity in multiple sclerosis, and muscular symptoms in motor neurone disease, and the psychological condition of generalized anxiety disorder. However, in many countries, gabapentin and pregabalin are frequently prescribed outside the terms of their market authorisations, and non-prescribed use has become widespread and troublesome in many populations. Increasing concerns regarding non-prescribed use have led some regulatory authorities to designate gabapentin and pregabalin as controlled substances, with accompanying regulations regarding prescriptions. This review describes the pharmacological properties of gabapentin and pregabalin, highlights evidence regarding efficacy and tolerability, summarises the findings of investigations of potential hazards with these drugs, and concludes with guidance on the clinical management of non-prescribed use.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The role of community and district nurses Promoting equity in community nursing Social prescribing: the view from the VCSE sector How to read a research paper How to behave in an interview with the media
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1